Parkside Scientific Inc

Parkside Scientific Inc., based in New York City, is revolutionizing drug discovery by focusing on a systems-level strategy that targets the epigenome and transcriptome to address the root causes of disease. By moving beyond traditional one-drug one-target approaches, the company aims to restore healthy cell function and overcome the challenges of resistance and toxicity in therapeutic treatments.

One of Parkside's notable innovations is its proprietary STAMP platform, which enables multi-target modulation of acetyl-mediated transcriptional regulators, resulting in lower doses and reduced toxicity. With ongoing clinical trials for its lead candidate PS1132 in hematologic malignancies, Parkside is expanding its research to include treatment-resistant prostate and breast cancer, as well as chronic inflammatory conditions like IBD and Alzheimer's disease.

Generated from the website